PMID- 33096115
OWN - NLM
STAT- MEDLINE
DCOM- 20201231
LR  - 20201231
IS  - 1879-0631 (Electronic)
IS  - 0024-3205 (Linking)
VI  - 264
DP  - 2021 Jan 1
TI  - The mother relationship between insulin resistance and non-alcoholic 
      steatohepatitis: Glucosinolates hydrolysis products as a promising insulin 
      resistance-modulator and fatty liver-preventer.
PG  - 118615
LID - S0024-3205(20)31368-0 [pii]
LID - 10.1016/j.lfs.2020.118615 [doi]
AB  - Non-alcoholic fatty liver disease (NFLD) is one of the present public health 
      problems which have no specific and effective treatment. The speed of the disease 
      progression depends on the patient's lifestyle. Due to life stresses and lack of 
      time, a high number of people depend on fast food containing a high amount of 
      fats which one of the main causes of insulin resistance (IR). IR is one of the 
      metabolic disorders which strongly intersected with molecular NAFLD and leading 
      to its progression into non-alcoholic steatohepatitis (NASH). In this review, we 
      introduced the updated statistics of NAFLD and NASH progression all over the 
      world shows its importance, etiologies, and pathogenesis. Also, IR and its role 
      in NASH initiation and progression explored, and current treatments with its 
      limitations have been explained. Glucosinolates (GLS) is a group of 
      phytochemicals which known by its potent hydrolysis products with promising 
      anti-cancer effect. In this review, we have collected the recent experimental 
      studies of different GLS hydrolysis products against IR and chronic liver 
      diseases supported by our lab finding. Finally, we recommend this group of 
      phytochemicals as promising molecules to be studied experimentally and clinically 
      against a wide range of chronic liver diseases with an acceptable safety margin.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Mohammed, Eman D
AU  - Mohammed ED
AD  - Department of Clinical Pharmacology, Nanjing Drum Tower Hospital, Pharmacy 
      Collage of Nanjing Medical University, Nanjing 210000, Jiangsu Province, China; 
      Department of Hepatobiliary Surgery, The Affiliated Drum Tower Hospital of 
      Nanjing University Medical School, Nanjing 210093, Jiangsu Province, China; 
      Natural Products Unit, Medicinal and Aromatic Plants Department, Desert Research 
      Centre, Cairo, Egypt.
FAU - Abdel-Naim, Ashraf B
AU  - Abdel-Naim AB
AD  - Department of Pharmacology and Toxicology, Faculty of Pharmacy, King Abdulaziz 
      University, Jeddah, Saudi Arabia.
FAU - Kangpeng, Jin
AU  - Kangpeng J
AD  - Department of Hepatobiliary Surgery, The Affiliated Drum Tower Hospital of 
      Nanjing University Medical School, Nanjing 210093, Jiangsu Province, China.
FAU - Jiang, Runqiu
AU  - Jiang R
AD  - Department of Hepatobiliary Surgery, The Affiliated Drum Tower Hospital of 
      Nanjing University Medical School, Nanjing 210093, Jiangsu Province, China.
FAU - Wei, Jifu
AU  - Wei J
AD  - Research Division of Clinical Pharmacology, The First Affiliated Hospital, 
      Pharmacy College of Nanjing Medical University, Nanjing 210000, Jiangsu Province, 
      China.
FAU - Sun, Beicheng
AU  - Sun B
AD  - Department of Hepatobiliary Surgery, The Affiliated Drum Tower Hospital of 
      Nanjing University Medical School, Nanjing 210093, Jiangsu Province, China; 
      Nanjing Drum Tower Hospital, Clinical College of Nanjing Medical University, 
      Nanjing 210000, Jiangsu Province, China. Electronic address: sunbc@nju.edu.cn.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201021
PL  - Netherlands
TA  - Life Sci
JT  - Life sciences
JID - 0375521
RN  - 0 (Dietary Fats)
RN  - 0 (Glucosinolates)
RN  - 0 (Phytochemicals)
SB  - IM
MH  - Dietary Fats/adverse effects/metabolism
MH  - Female
MH  - Glucosinolates/*administration & dosage/metabolism
MH  - Humans
MH  - Hydrolysis
MH  - Insulin Resistance/*physiology
MH  - Non-alcoholic Fatty Liver Disease/*diet therapy/etiology/metabolism
MH  - Phytochemicals/*administration & dosage/metabolism
MH  - *Risk Reduction Behavior
OTO - NOTNLM
OT  - Anti-fibrosis
OT  - Glucosinolates
OT  - Insulin resistance
OT  - Isothiocyanates
OT  - Nitriles
OT  - Non-alcoholic steatohepatitis
EDAT- 2020/10/24 06:00
MHDA- 2021/01/01 06:00
CRDT- 2020/10/23 20:10
PHST- 2020/09/18 00:00 [received]
PHST- 2020/10/09 00:00 [revised]
PHST- 2020/10/14 00:00 [accepted]
PHST- 2020/10/24 06:00 [pubmed]
PHST- 2021/01/01 06:00 [medline]
PHST- 2020/10/23 20:10 [entrez]
AID - S0024-3205(20)31368-0 [pii]
AID - 10.1016/j.lfs.2020.118615 [doi]
PST - ppublish
SO  - Life Sci. 2021 Jan 1;264:118615. doi: 10.1016/j.lfs.2020.118615. Epub 2020 Oct 
      21.